Perioperative medicine & outcomes
Intraoperative methylene blue infusion reduces postoperative delirium in patients undergoing pancreatic surgery: A randomized controlled clinical trial
Authors' conclusion
Intraoperative methylene blue use effectively and safely reduced the POD incidence in patients undergoing pancreatic surgery, which may be associated with decrease in systemic inflammation and immunovascular interactions.
Study context
- Population
- Patients scheduled for pancreatic surgery at a university cancer center
- Participants
- 314 patients
- Comparison
- Intraoperative methylene blue vs saline
- Primary endpoint
- POD incidence
Methodological detailssingle blind, University cancer center
- Single blind
- University cancer center
Primary result
As reported in the abstract
P = 0.005
- Postoperative delirium (POD) overall
- 55 (17.5%)
Secondary outcomes
Postoperative plasma IL-6 and IL-8
- Postoperative IL-6 but not IL-8 lower in the methylene blue group
Endothelial gene expression and PBMC adhesion to hCMEC/d3 cells
- Endothelial TNF-α, MCP-1 and VCAM1 expressions lower with serum from the methylene blue group
- Fewer peripheral blood mononuclear cells (PBMCs) adhering to hCMEC/d3 cells in the methylene blue group
Safety
Perioperative adverse events
- Comparable in the two groups
Original publication
Intraoperative methylene blue infusion reduces postoperative delirium in patients undergoing pancreatic surgery: A randomized controlled clinical trial. J Clin Anesth. Published 1 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →